Tirofiban
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1998
- First approval year
- 1998
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Tirofiban
- Molecular weight
- 440.61
- Structure (SMILES)
- CCCCS(=O)(=O)N[C@@H](Cc1ccc(OCCCCC2CCNCC2)cc1)C(=O)O
- agrastat
- Agrastat
- tirofiban
- Tirofiban
- TIROFIBAN [HSDB]
- tirofiban [INN]
- TIROFIBAN [MI]
- TIROFIBAN [VANDF]
- Tirofiban [WHO-DD]
- tirofiban hsdb
- tirofiban inn
- tirofiban mi
- tirofiban vandf
- tirofiban who dd
- ATC classification codes
- B01AC17
Sources for recorded values
- CAS registry numbers
- 144494-65-5
- ChEMBL ID
- CHEMBL916
- InChIKey
- COKMIXFXJJXBQG-NRFANRHFSA-N
- FDA ingredient codes (UNII)
- GGX234SI5H
- 60947
- 40466968
- 73137
- 253202
- Applicant
- MEDICURE
- Approval date
- 14 May 1998
- Application number
- NDA020912
- First in class
- No
- Orphan designation
- No
- Availability
- Prescription only
- United States (FDA)
- Approved
- Pharmacology name
- tirofiban
- Type
- Synthetic organic
- Drug name stem
- -fiban
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- Parenteral
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- integrin αIIbβ3
- Gene symbol
- ITGA2B
- Protein identifier
- P05106
- Median affinity
- 9.43
- Affinity units
- pIC50
- Primary target
- Yes
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- integrin αIIbβ3
- Gene symbol
- ITGB3
- Protein identifier
- P08514
- Median affinity
- 9.43
- Affinity units
- pIC50
- Primary target
- Yes
Open Targets mechanisms
- Mechanism
- Integrin alpha-IIb/beta-3 inhibitor
- Action type
- Inhibitor
- Target
- Integrin alpha-IIb/beta-3
DrugCentral mechanisms
- Action type
- Inhibitor
- Gene symbol
- ITGB3|ITGA2B
- Protein identifier
- P05106|P08514
- Organism
- Homo sapiens
- Target development level
- Clinical
- Condition
- Myocardial Infarction
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000612
- Subject identifier
- D009203
- Condition
- Stroke
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000712
- Subject identifier
- D020521
- Condition
- Coronary Disease
- Highest recorded phase
- 3
- Condition identifier
- EFO:0001645
- Subject identifier
- D003327
- Condition
- Atherosclerosis
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003914
- Subject identifier
- D050197
- Condition
- Venous Thromboembolism
- Highest recorded phase
- 2
- Condition identifier
- EFO:0004286
- Subject identifier
- D054556
- Condition
- Acute Coronary Syndrome
- Highest recorded phase
- 3
- Condition identifier
- EFO:0005672
- Subject identifier
- D054058
- Condition
- Pneumonia, Viral
- Highest recorded phase
- 2
- Condition identifier
- EFO:0007541
- Subject identifier
- D011024
- Condition
- Myocardial Infarction
- Highest recorded phase
- 3
- Condition identifier
- EFO:0008583
- Subject identifier
- D009203
- Condition
- Respiratory Insufficiency
- Highest recorded phase
- 2
- Condition identifier
- EFO:0009686
- Subject identifier
- D012131
- Condition
- Renal Insufficiency
- Highest recorded phase
- 1
- Condition identifier
- HP:0000083
- Subject identifier
- D051437
- Condition
- Ischemic Stroke
- Highest recorded phase
- 2
- Condition identifier
- HP:0002140
- Subject identifier
- D000083242
- Condition
- Thrombosis
- Highest recorded phase
- 4
- Condition identifier
- HP:0004419
- Subject identifier
- D013927
- Condition
- Severe Acute Respiratory Syndrome
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0100096
- Subject identifier
- D045169
- Condition identifier
- EFO_0000612
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000712
- Condition identifier
- EFO_0001645
- Highest recorded phase
- 3
- Condition identifier
- EFO_0005672
- Condition identifier
- EFO_0008583
- Highest recorded phase
- 3
- Condition identifier
- HP_0000083
- Highest recorded phase
- 1
- Condition identifier
- HP_0001297
- Highest recorded phase
- 3
- Condition identifier
- HP_0002140
- Highest recorded phase
- 3
- Condition identifier
- HP_0004419
- Condition identifier
- HP_0004419
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0001106
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0004781
- Condition identifier
- MONDO_0005010
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005068
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005098
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005098
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005099
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005542
- Highest recorded phase
- 4
- Condition identifier
- MONDO_1060198
- Highest recorded phase
- 3
- Event
- abdominal discomfort
- Reports
- 1
- Reporting signal score
- 8.2813
- Event
- abdominal pain
- Reports
- 5
- Reporting signal score
- 12.8396
- Event
- abdominal pain upper
- Reports
- 1
- Reporting signal score
- 12.1071
- Event
- acute kidney injury
- Reports
- 1
- Reporting signal score
- 14.6134
- Event
- acute myocardial infarction
- Reports
- 14
- Reporting signal score
- 7.77274
- Event
- angina pectoris
- Reports
- 129
- Reporting signal score
- 335.801
- Event
- anxiety
- Reports
- 1
- Reporting signal score
- 15.718
- Event
- arrhythmia
- Reports
- 28
- Reporting signal score
- 29.0962
- Event
- asthenia
- Reports
- 1
- Reporting signal score
- 30.4318
- Event
- atrial fibrillation
- Reports
- 1
- Reporting signal score
- 7.52315
- Event
- back pain
- Reports
- 3
- Reporting signal score
- 11.2835
- Event
- blood pressure increased
- Reports
- 1
- Reporting signal score
- 8.46476
- Event
- capsular warning syndrome
- Reports
- 4
- Reporting signal score
- 26.1662
- Event
- cardiac failure
- Reports
- 62
- Reporting signal score
- 79.5914
- Event
- cardiac failure acute
- Reports
- 11
- Reporting signal score
- 20.6309
- Event
- cerebral haemorrhage
- Reports
- 86
- Reporting signal score
- 211.949
- Event
- condition aggravated
- Reports
- 1
- Reporting signal score
- 24.4328
- Event
- coronary artery restenosis
- Reports
- 4
- Reporting signal score
- 9.49702
- Event
- coronary artery stenosis
- Reports
- 10
- Reporting signal score
- 15.4602
- Event
- coronary revascularisation
- Reports
- 18
- Reporting signal score
- 104.379
- Event
- device embolisation
- Reports
- 4
- Reporting signal score
- 15.8812
- Event
- diarrhoea
- Reports
- 3
- Reporting signal score
- 51.0923
- Event
- dizziness
- Reports
- 3
- Reporting signal score
- 35.7149
- Event
- drug hypersensitivity
- Reports
- 5
- Reporting signal score
- 16.2231
- Event
- drug interaction
- Reports
- 7
- Reporting signal score
- 8.61224
And 60 more, listed on the interactive page.
- NCT00251576
- NCT01660373
- NCT01109134
- NCT01336348
- NCT01598337
- NCT03078257
- NCT01766154
- NCT03357133
- NCT04818944
- NCT04851457
- NCT05188417
- NCT04368377
- NCT04491695
- NCT05728333
- NCT06037889
- Dose
- 25 mcg/kg
- Route
- Intravenous
- How often
- Up to 18 hours
- Administer within 5 minutes
- Use premixed bag for bolus and infusion
- Hydrogen bond acceptors
- 5
- Hydrogen bond donors
- 3
- Polar surface area
- 104.73
- Calculated partition coefficient (ALogP)
- 2.95
- Calculated partition coefficient (XLogP)
- 1.4
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 14
- Heavy atoms
- 30
- Molecular formula
- C22H36N2O5S
- Monoisotopic mass
- 440.23449343
- Natural product
- Yes
- Recorded assays
- 316
- Active assays
- 81
Active assay types
- Confirmatory
- Fibrinolytic Agents
- Platelet Aggregation Inhibitors
Related records
Trials (55)
- A Multicenter, Three-Arm, Open-Label, Endpoint-Blinded Randomized Controlled Trial to Evaluate the Optimal Duration of Early Tirofiban After Intravenous Thrombolysis in Acute Ischemic Stroke
- A Study Evaluating the Safety and Efficacy of Tirofiban in Combination With Alteplase in Acute Ischemic Stroke
- Aggrastat Truncated Length Against Standard Therapies in Percutaneous Coronary Intervention
- Antiplatelet Effects of Tirofiban vs. Cangrelor N-STEMI Patients Undergoing Percutaneous Coronary Intervention
- ATILA Project: Aspirin Versus Tirofiban in Endovascular Treatment for Patients With Acute Ischemic Stroke Due to Tandem Lesion
- BivaliRudin in Acute Myocardial Infarction vs Glycoprotein IIb/IIIa and Heparin :a Randomised Controlled Trial.
- Comparison of Antiplatelet Effect of Ticagrelor vs Tirofiban in Patients With Non-ST Elevation Acute Coronary Syndrome
- Comparison of Two Treatment Strategies in Patients With an Acute Coronary Syndrome Without ST Elevation
- Early Initiation of Low Dose Tirofiban for PPCI in STEMI Patients.
- Early Tirofiban Administration After Intravenous Thrombolysis in Acute Ischemic Stroke
- Effect of Upstream High Bolus Dose of Tirofiban in Primary PCI for the Patients With STEMI on Short Term Outcome
- Effects of Intracoronary Prourokinase on the Coronary Flow During Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction
- Efficacy and Safety of Different Dose of Tirofiban in Interventional Treatment of Complex Coronary Artery Disease
- Efficacy and Safety of Tirofiban for Patients With BAD (BRANT)
- Endovascular Therapy Combined With Tirofiban for Intracranial Atherosclerotic Acute Ischemic Stroke
- Enhanced Platelet Inhibition in Critically Ill Patients With COVID-19
- Facilitation Through Aggrastat By drOpping or Shortening Infusion Line in Patients With ST-segment Elevation Myocardial Infarction Compared to or on Top of PRasugrel Loading dOse
- FATA: Randomized Study on Facilitated Angioplasty With Tirofiban or Abciximab
- GPIIbIIIa Inhibitors in the RESCUe and RESURCOR Networks at the Acute Myocardial Infarction
- HR-MRI-Directed Tirofiban Therapy for Late-Window Acute Ischemic Stroke (TIAN)
Approved for (1)
In development for (13)
- Acute coronary syndrome Phase 3
- Acute myocardial infarction Phase 3
- Atherosclerosis Phase 3
- Coronary artery disorder Phase 3
- COVID-19 Phase 2
- Ischemic stroke Phase 2
- Kidney failure Phase 1
- Myocardial infarction Phase 3
- Respiratory failure Phase 2
- Stroke disorder Phase 2
- Subarachnoid hemorrhage Phase 1
- Venous thromboembolism Phase 2
- Viral pneumonia Phase 2